The discriminatory value of CYP2D6 genotyping in predicting the dextromethorphan/dextrorphan phenotype in women with breast cancer

Breast Care

Volumn 7, Issue 1, 2012, Pages 25-31

  Trojan, Andreas ^a,b,f   Vergopoulos, Athanasios ^b,e   Breitenstein, Urs ^a,b   Seifert, Burkhardt ^c   Rageth, Christoph ^b   Joechle, Wolfgang ^d  

^a KLINIK IM PARK   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e Laboratory Enders and Partner   (Germany)

^f Brust Zentrum Zurich   (Switzerland)

Author keywords

Breast cancer; CYP2D6; Dextromethorphan Dextrorphan; Genotype; Phenotype

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN;

ARTICLE; BREAST CANCER; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; METABOLIC CAPACITY; PHARMACOGENOMICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; URINALYSIS;

EID: 84858641580     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000336551     Document Type: Article

References (42)

1. Brauch H, Muerdter TE, Eichelbaum M, Schwab M: Pharmacogenetics of tamoxifen therapy. Clin Chem 2009;55:1770-1782.
2. Barrière J, Formento JL, Milano G, Ferrero JM: CYP2D6 polymorphisms and therapeutic perspectives in the management of hormone-dependent breast cancer patients. Bull Cancer 2010;97:311-320.
3. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-39.
4. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-1764. (Pubitemid 38008898)
5. Johnson MD, Zuo H, Lee KH, JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004;85:151-159. (Pubitemid 38987269)
6. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA: Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80:61-74. (Pubitemid 43946844)
7. Schroth W, Goetz M, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302:1429-1436.
8. Newman WG, Hadfield KD, Latif A, Roberts SA, Shenton A, McHague C, Lalloo F, Howell S, Evans DG: Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 2008;14:5913-5918.
9. Ramón y Cajal T, Altés A, Paré L, del Rio E, Alonso C, Barnadas A, Baiget M: Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 2010;119:33-38.
10. Bijl MJ, van Schaik RH, Lammers LA, Hofman A, Vulto AG, van Gelder T, Stricker BH, Visser LE: The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 2009;118:125-130.
11. Okishiro M, Taguchi T, Jin KS, Shimazu K, Tamaki Y, Noguchi S: Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 2009;115:952-961.
12. Xu Y, Sun Y, Yao L, Shi L, Wu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, He L, Li P, Xie Y: Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 2008;19:1423-1429.
13. Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, Pierce JP: Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 2008;108:421-426. (Pubitemid 351431079)
14. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. Clin Oncol 2005;23:9312-9318.
15. Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S: Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 2009;10:825-833.
16. Punglia RS, Burstein HJ, Winer EP, Weeks JC: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 2008;100:642-648.
17. Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philips S, Nguyen A, Stearns V, Hayes D, Rae JM, Skaar TC, Flockhart DA, Li L: Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 2010;50:450-458.
18. Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, Wingren S: Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007;9:R7.
19. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H: Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 2010;28:1287-1293.
20. Langan-Fahey SM, Tormey DC, Jordan VC: Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 1990;26:883-888.
21. Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL: Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2004;96:883-885. (Pubitemid 38807611)
22. Bock KW, Schrenk D, Forster A, Griese EU, Mörike K, Brockmeier D, Eichelbaum M: The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994;4:209-218. (Pubitemid 24269825)
23. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS: The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008;83:234-242.
24. Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS Jr: Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, Nacetyltransferase-2, and xanthine oxidase with the 'Cooperstown cocktail'. Clin Pharmacol Ther 2000;68:375-383.
25. Ducharme J, Abdullah S, Wainer IW: Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 1996;678:113-128. (Pubitemid 26114747)
26. Hersberger M, Marti-Jaun J, Rentsch K, Hänseler E: Rapid detection of the CYP2D6*3, CYP2D6*4 and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 2000;46:1072-1077. (Pubitemid 30643307)
27. Steijns LS, Van der Weide J: Ultrarapid drug metabolism: PCR-based detection CYP2D6 gene duplication. Clin Chem 1998;44:914-917. (Pubitemid 28213128)
28. Yu A, Haining RL: Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: Can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities. Drug Metab Dispos 2001;29:1514-1520. (Pubitemid 33000701)
29. Abdel-Rahman SM, Leeder JS, Wilson JT, Gaedigk A, Gotschall RR, Medve R, Liao S, Spielberg SP, Kearns GL: Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol 2002;42:24-29. (Pubitemid 34038366)
30. Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C, James LP, Wilson JT, Kearns GL, Leeder JS: Ontogeny of dextromethorphan O-and N-demethylation in the first year of life. Clin Pharmacol Ther 2007;81:510-516. (Pubitemid 46452306)
31. Brauch H, Schroth W: CYP2D6-Tamoxifen Pharmakogenetik beim frühen Mammakarzinom. Gynakologe 2010;43:579-585.
32. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Paszat LF: Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010;340:c693.
33. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, MacLeod SL, Kadlubar FF, Ambrosone CB: Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005;91:249-258. (Pubitemid 40903087)
34. Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A: Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 2009;116:491-500.
35. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Pineda S, Cuzick J, Dowsett M: Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. San Antonio Breast Cancer Symposium (SABCS) 2010;abstr S1-7, www.abstracts2view.com/ sabcs10/view.php?nu = SABCS10L-1093.
36. Leyland-Jones B, Regan MM, Bouzyk M, Kammler R, Tang W, Pagani O, Maibach R, Dell'Orto P, Thurlimann B, Price KN, Viale G: Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. San Antonio Breast Cancer Symposium (SABCS) 2010;abstr S1-8, www.abstracts2view. com/sabcs10/view.php?nu = SABCS10L-556.
37. Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, Skaar TC, Nguyen AT, Desta Z, Storniolo AM, Flockhart DA, Hayes DF, Stearns V: Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 2009;9:258-264.
38. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-121. (Pubitemid 47555336)
39. Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, Latif A, Hadfield KD, Clarke RB, Ashcroft L, Evans DG, Howell A, Nikoloff M, Lawrence J, Newman WG: Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 2011;125:279-287.
40. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, Mellgren G, Steen VM, Lien EA: Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 2008;19:56-61.
41. McElroy S, Sachse C, Brockmoller J, Richmond J, Lira M, Friedman D, Roots I, Silber BM, Milos PM: CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS PharmSci 2000;2:E33.
42. de Graan AJ, Teunissen SF, de Vos FY, Loos WJ, van Schaik RH, de Jongh FE, de Vos AI, van Alphen RJ, van der Holt B, Verweij J, Seynaeve C, Beijnen JH, Mathijssen RH: Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol 2011;29:3240-3246.